BRIN-BD11

NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA, 10033003, rat pancreas (islets), Epitheloid

• Sinónimos: BRIN
• UNSPSC Code: 41106514

Propiedades

• biological source: rat pancreas (islets)
• packaging: tube of 5 μg 10033003-DNA-5UG; pkg of vial of cells 10033003-1VL
• growth mode: Not specified
• karyotype: Modal chromosome number 58 over 50 passages
• morphology: Epitheloid
• products: BRIN-BD11 is a stable, glucose-responsive insulin secreting beta cell line expressing insulin, glucokinase and IAPP as detected by immunocytochemistry. BRIN-BD11 cells express the GLUT2 glucose transporter.
• receptors: Not specified
• technique(s): cell culture | mammalian: suitable
• shipped in: dry ice

Descripción

Cell Line Origin

A rat pancreatic Beta cell: RINm5F hybrid cell line. Insulin-secreting cell line

Cell Line Description

BRIN-BD11 is a hybrid cell line formed by the electrofusion of a primary culture of NEDH rat pancreatic islets with RINm5F (a cell line derived from a NEDH rat insuliinoma). BRIN-BD11 has been shown to be tumourigenic when transplanted into a SCID mouse host. BRIN-BD11 has been mycoplasma eradicated at ECACC and the stocks available for supply have undergone a further 10 passages without detection of mycoplasma. The cell line has applications in the study of pancreatic beta cell function.

DNA Profile

Not specified

Culture Medium

RPMI-1640 + 2 mM Glutamine + 10% FCS / FBS

Subculture Routine

Split sub-confluent cultures (70-80%) 1:8 to 1:10 , i.e., seeding at 2-4 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37 °C. Population doubling approx 20hrs. At confluence 10⁵ cells/cm² can be expected.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.